261 related articles for article (PubMed ID: 36102132)
21. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
Howlett S; Carter TJ; Shaw HM; Nathan PD
Ther Adv Med Oncol; 2023; 15():17588359231160140. PubMed ID: 36970111
[TBL] [Abstract][Full Text] [Related]
22. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
Klabusay M; Bábková B
Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
Fahmy LM; Schreidah CM; McDonnell DE; Carvajal RD; Magro CM; Geskin LJ
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478664
[TBL] [Abstract][Full Text] [Related]
24. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Hamid O; Hassel JC; Shoushtari AN; Meier F; Bauer TM; Salama AKS; Kirkwood JM; Ascierto PA; Lorigan PC; Mauch C; Orloff M; Evans TRJ; Holland C; Edukulla R; Abedin SE; Middleton MR
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286303
[TBL] [Abstract][Full Text] [Related]
25. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
Montazeri K; Pattanayak V; Sullivan RJ
Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760
[TBL] [Abstract][Full Text] [Related]
26. Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis.
Reichstein D; Brock A; Lietman C; McKean M
Curr Opin Ophthalmol; 2022 Nov; 33(6):585-590. PubMed ID: 36094043
[TBL] [Abstract][Full Text] [Related]
27. Review of bi-specific therapies in uveal melanoma.
Orloff M; Seedor R; Sato T
Cancer Gene Ther; 2022 Dec; 29(12):1814-1818. PubMed ID: 35236927
[TBL] [Abstract][Full Text] [Related]
28. Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.
Tomsitz D; Ruf T; Heppt M; Staeger R; Ramelyte E; Dummer R; Garzarolli M; Meier F; Meier E; Richly H; Gromke T; Siveke JT; Franklin C; Klespe KC; Mauch C; Kilian T; Seegräber M; Schilling B; French LE; Berking C; Heinzerling L
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444540
[TBL] [Abstract][Full Text] [Related]
29. Uveal melanoma: In the era of new treatments.
Wespiser M; Neidhardt E; Negrier S
Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
[TBL] [Abstract][Full Text] [Related]
30. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
31. Ensuring equity in the era of HLA-restricted cancer therapeutics.
Smithy JW; Blouin A; Diamond LC; Postow M
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442912
[TBL] [Abstract][Full Text] [Related]
32. Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond.
Gerard C; Shum B; Nathan P; Turajlic S
Immunooncol Technol; 2023 Sep; 19():100386. PubMed ID: 37483658
[TBL] [Abstract][Full Text] [Related]
33. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract][Full Text] [Related]
34. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
[TBL] [Abstract][Full Text] [Related]
35. Evolving Management of Stage IV Melanoma.
Switzer B; Piperno-Neumann S; Lyon J; Buchbinder E; Puzanov I
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e397478. PubMed ID: 37141553
[TBL] [Abstract][Full Text] [Related]
36. Successful application of chemosaturation with percutaneous hepatic perfusion in metastatic uveal melanoma patient progressing after systemic treatment options: a case report.
Gunenc D; Ozluk AA; Yıldırım UM; Ascierto PA; Karaca B
Front Oncol; 2024; 14():1355971. PubMed ID: 38660135
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of an orphan drug tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing.
Luo S; Xie C; Lin N; Lin D; Gu D; Lin S; Huang X; Xu X; Weng X
Melanoma Res; 2023 Dec; 33(6):525-531. PubMed ID: 37650713
[TBL] [Abstract][Full Text] [Related]
38. Metastatic uveal melanoma: The final frontier.
Rantala ES; Hernberg MM; Piperno-Neumann S; Grossniklaus HE; Kivelä TT
Prog Retin Eye Res; 2022 Sep; 90():101041. PubMed ID: 34999237
[TBL] [Abstract][Full Text] [Related]
39. Novel Approaches to the Systemic Management of Uveal Melanoma.
Khan S; Carvajal RD
Curr Oncol Rep; 2020 Jul; 22(10):104. PubMed ID: 32725406
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]